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Introduction
Methylphenidate hydrochloride (Ritalin), a short-acting
central nervous system stimulant, is common and effi-
cacious in the treatment of attention deficit hyperac-
tivity disorder (ADHD) in psychiatric clinic, especially
for children.1 It is a sympathomimetic amine and is
contraindicated in patients with glaucoma, as men-
tioned in the Physicians’ Desk Reference and package
insert. Glaucoma exacerbated by oral methylphenidate
has been reported in the literature.2 However, there has
been no report of methylphenidate-associated com-
plicated cataract. We present a case of bilateral com-
plicated cataract and glaucoma following large-dose
methylphenidate use for 2 years.
Case Report
A 10-year-old boy presented with progressive blurred
vision in both eyes over the past 1 year. He had no
history of systemic disease, ocular trauma or ocular dis-
order except myopia before this episode. His corrected
visual acuity was 6/7.5 in both eyes 1 year previously.
Decreased visual acuity was noted during routine school
physical check-up 3 months before this visit. Glaucoma
and cataract were diagnosed at the ophthalmic clinic.
The patient was referred to our department due to
poorly controlled intraocular pressure (IOP) under
2% carteolol eye drops twice a day. His best corrected
visual acuity (BCVA) was 6/60 with sph −5.25 cyl 
−1.5 × 160° in the right eye and 6/60 with sph −5.25
cyl −0.75 × 40° in the left eye on presentation.
Slit-lamp biomicroscopy revealed clear cornea, deep
anterior chamber, and dense posterior subcapsular
opacity of lens in both eyes (Figure 1). Gonioscopy
showed Grade 4 open (Shaffer system) and well devel-
oped angle. Indirect ophthalmoscopy revealed pale disc
with advanced glaucoma cupping (0.9 × 0.9) in both
eyes. IOP was 26 mmHg in both eyes. Automated
perimetry revealed generalized visual field constriction
in the right eye and upper arcuate scotoma in the left
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eye. The patient had ADHD and had been taking
methylphenidate hydrochloride (Ritalin) 40 mg/day in
2 divided doses as prescribed by his psychiatrist. How-
ever, his mother had increased the dose to 60 mg/day
for the past 2 years. Otherwise, his mother denied 
any other medication including steroid and herbs or
any ocular trauma history.
Under the impression of methylphenidate-associated
cataract and glaucoma, latanoprost every night, 2%
carteolol twice a day for both eyes and oral acetazol-
amide 125mg twice a day were given. Methylphenidate
was discontinued. Despite maximal antiglaucomatous
medications for 1 month, IOP still fluctuated up to
30 mmHg in both eyes. The patient underwent tra-
beculectomy and phacoemulsification with intraocu-
lar lens implantation for both eyes. IOP was maintained
around 16 mmHg in both eyes, and BCVA was 6/6
in the right eye and 6/12 in the left eye at 1 year of
follow-up.
Discussion
When glaucoma is encountered in children, the usual
first thought is congenital glaucoma. In the congeni-
tal glaucomatous eye, we can see Haab’s striae on the
cornea and underdeveloped mesodermal tissue over the
chamber angle by gonioscopy. In our patient, the cornea
was clear without any striation. Gonioscopy showed a
well developed wide open angle without any residue
mesodermal tissue. Congenital glaucoma was therefore
ruled out.
In congenital cataract, one can usually see snowflake
or sclerosis of the lens nucleus. In our patient, only
posterior subcapsular opacity with clear nucleus could
be seen. If the lens displays posterior subcapsular opac-
ity, our first consideration would be complicated cataract
related to topical steroid use, diabetes, hyperthyroidism,
systemic medications such as phenothiazines, amio-
darone, steroid and herbs, etc.3 However, none of the
above were found in our patient.
A child with ADHD is prone to head trauma. This
could induce traumatic cataract. In such situations,
lens subluxation or nucleus milky change would be
found. None of that was found in our case, so traumatic
cataract was also ruled out.
Methylphenidate is a sympathomimetic amine. It has
the potential to induce acute angle closure glaucoma
or worsen chronic angle closure glaucoma.2,4,5 The
Physicians’ Desk Reference indicates that the maximum
daily dosage is 60 mg, and a dosage > 60 mg/day is not
recommended. Our patient took a high dose of the
medication for 2 years. A characteristic glaucomatous
optic neuropathy with associated visual field defect and
elevated IOP, and complicated cataract in both eyes
were noted. Since the congenital factor was not likely,
and there were no other medication- or trauma-related
factors, the possibility of prolonged high-dose Ritalin
use-related complicated cataract and glaucoma was our
first consideration.
Despite discontinuation of methylphenidate, dense
cataract and persistent high IOP caused severe vision
loss in both eyes. One possible mechanism is that
methylphenidate may cause cytoskeletal change in the
chamber angle trabecular meshwork or obstruction of
trabecular meshwork. Even after the discontinuation
of methylphenidate, the function of the trabecular
meshwork did not recover. Therefore, the glaucoma
remained out of control. Filtering surgery for glaucoma
management was necessary.
From the literature, no report of Ritalin-related
cataract has been found. This is the first report of
methylphenidate-associated cataract and glaucoma.
Although the underlying mechanism is unknown, the
possible ocular side effects should be considered in
patients on methylphenidate treatment.
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Figure 1. Slit-lamp biomicroscopy of the patient’s right eye shows
dense posterior subcapsular lens opacity.
